No connection

Search Results

CTEV vs JNJ

CTEV
Claritev Corporation
BEARISH
Price
$23.81
Market Cap
$404.0M
Sector
Healthcare
AI Confidence
85%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
CTEV
--
JNJ
21.55
Forward P/E
CTEV
3.48
JNJ
18.9
P/B Ratio
CTEV
-2.27
JNJ
7.03
P/S Ratio
CTEV
0.42
JNJ
6.09
EV/EBITDA
CTEV
9.35
JNJ
17.81

Profitability

Gross Margin
CTEV
73.75%
JNJ
68.08%
Operating Margin
CTEV
9.77%
JNJ
23.97%
Profit Margin
CTEV
-29.45%
JNJ
28.46%
ROE
CTEV
--
JNJ
35.03%
ROA
CTEV
1.12%
JNJ
8.68%

Growth

Revenue Growth
CTEV
6.2%
JNJ
9.1%
Earnings Growth
CTEV
--
JNJ
48.6%

Financial Health

Debt/Equity
CTEV
--
JNJ
0.6
Current Ratio
CTEV
0.86
JNJ
1.03
Quick Ratio
CTEV
0.6
JNJ
0.69

Dividends

Dividend Yield
CTEV
--
JNJ
2.19%
Payout Ratio
CTEV
0.0%
JNJ
46.6%

AI Verdict

CTEV BEARISH

CTEV exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price-to-Book ratio of -2.27, indicating negative shareholder equity. While the company maintains strong gross margins (73.75%) and a low Price-to-Sales ratio (0.42), these are overshadowed by catastrophic earnings volatility and a 5-year price collapse of 91.9%. The current liquidity position is precarious with a current ratio of 0.86, suggesting an inability to cover short-term obligations. Despite bullish analyst targets, the deterministic data points to a high-risk value trap.

Strengths
Strong Gross Margin of 73.75%
Positive Operating Margin of 9.77%
Low Price-to-Sales ratio (0.42) suggesting undervaluation relative to revenue
Risks
Negative Book Value (P/B -2.27) indicating insolvency risk
Weak Piotroski F-Score (2/9) signaling deteriorating fundamental health
Liquidity risk with Current Ratio (0.86) and Quick Ratio (0.60) below 1.0
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

CTEV vs JNJ: Head-to-Head Comparison

This page compares Claritev Corporation (CTEV) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile